The core technology of Reber Genetics is to combine two of the latest genetic engineering techniques, “reverse genetic engineering” and “fusion protein platform” to develop a series of targeted subunit animal vaccines.
The technology of this novel vaccine platform uses a targeted drug delivery system to promote the binding affinity to antigen presenting cells, and uses a specific signal peptide to induce antigens to present on the cell surface through the MHC-I pathway, successfully activating cytotoxic T cell.
This activates cytotoxic T cells to remove the cells which had been infected by the pathogen, thereby preventing disease.
This patented technology can be applied to the prevention of other important animal diseases such as Porcine Circo Virus 2, Foot-and-Mouth disease (FMD), Porcine Epidemic Diarrhea (PED), and combination products. Furthermore, in addition to production animals, this technology can also be used in the growing pet market.